129 results about "High affinity binding" patented technology

The invention discloses a bipeptide modified bionic nano-vesicle as well as a preparation method and application thereof, and belongs to the field of biological medicines. The dipeptide modified bionic nano-vesicle comprises nano-particles formed by PLGA (poly (lactic-co-glycolic acid)), and the nano-particles are loaded with a medicine with a nerve protection or nerve repair effect; the surface of the nanoparticle is coated with a macrophage membrane for expressing RVG peptide and T7 peptide. The bipeptide modified bionic nano-vesicle simultaneously presents T7 peptide and RVG peptide through an engineered macrophage membrane, the T7 peptide is combined with a blood-brain barrier transferrin receptor through high affinity to realize efficient brain entry, astrocytes in the brain are specifically recognized by virtue of the RVG peptide, accurate recognition and delivery of target cells in a focus area are realized, and the bipeptide modified bionic nano-vesicle has a good application prospect. Meanwhile, the natural inflammation tropism and immune escape ability of a macrophage membrane are reserved, and the problems that a traditional drug delivery system is low in targeting precision, and cross-barrier distribution and intracerebral distribution are difficult to cooperate are solved.

The present invention relates to compounds which can bind to KLHDC2 (Kelch Domain-Containing Protein 2) E3 ubiquitin ligase with high-affinity, and bifunctional degraders containing such compounds.

The invention relates to the technical field of organic detection, in particular to a nanoparticle modified quantum dot MOF material and a preparation method and application thereof. A zirconium-based double-ligand metal organic framework material is used as a carrier, a co-reaction accelerant Ti3C2 quantum dot is modified to enhance the electrochemical luminescence reaction efficiency, and copper-gold nanoparticles are loaded to amplify signals. The nanoparticle modified quantum dot MOF material provided by the invention can be prepared into an aptamer biosensor for accurately identifying malathion, and has high sensitivity and high selectivity. According to the invention, a nanoparticle modified quantum dot MOF material is coupled and combined with an aptamer, and an aptamer probe with high electrochemical luminescence activity and specific sensitivity to malathion is constructed. When the malathion acts on the aptamer probe, the malathion is combined with the aptamer in a high affinity manner, the aptamer probe is separated from the surface of the electrode, and meanwhile, an electrochemical luminescence signal is changed, so that the malathion residue in the agricultural product is rapidly detected.

The invention discloses a preparation method and application of a cat main allergen FEL-1 nano antibody FEL-1-Nb, and relates to the technical field of antibody preparation, and the preparation method comprises the following steps: preparing an immunogen; animal immunization and library construction; constructing and panning a phage display library; screening and identifying positive clone; and expression and purification of the nano antibody: cloning the positively cloned VHH gene to an expression vector such as a pET series, transforming an expression strain such as escherichia coli BL21 (DE3), carrying out IPTG induced expression, and purifying through an inclusion body purification method to obtain a high-purity nano antibody protein. The nano antibody FEL-1-Nb provided by the invention can be specifically bound with a cat main allergen FEL-1 protein, the unique amino acid sequence of the nano antibody FEL-1-Nb is shown as SEQIDNO: 1, high-affinity binding with the FEL-1 protein is ensured, the positive clone binding rate is high through phage display panning and ELISA verification, the phage recovery rate after the third round of panning is increased by more than 1000 times compared with the first round of panning, and the positive clone binding rate is higher than that of the first round of panning. Therefore, the nano antibody has excellent targeted recognition capability.

The invention discloses a medicinal and edible active component-small molecule peptide-nano-selenium synergistic anti-aging composition screened based on a molecular docking technology, and belongs to the technical field of functional foods and biological medicines. The composition comprises an active ingredient with homology of medicine and food, a specific molecular polypeptide Ala-Val-His-Leu-Cys-Gly-Phe-Asp-Glu-Ser-Thr-Lys-Arg-Tyr-Pro and nano-selenium, wherein the active ingredient with homology of medicine and food is screened by a molecular docking technology and is combined with senescence-related targets Nrf2 and / or SIRT1 in a high affinity manner, and the active ingredient, the specific molecular polypeptide and the nano-selenium form an active ingredient-molecular polypeptide-nano-selenium ternary complex with homology of medicine and food. The preparation method comprises the following steps: screening the medicinal and edible active ingredients meeting conditions, preparing the molecular polypeptide, mixing the medicinal and edible active ingredients to form a compound, adding the nano-selenium, stirring and combining, and freeze-drying to obtain a finished product. The composition can be prepared into an oral preparation or an external preparation, has a multi-dimensional synergistic efficient anti-aging effect of an active ingredient targeted activation pathway, direct anti-oxidation of nano-selenium and enhanced delivery of a peptide carrier, and is suitable for preparation of anti-aging drugs or functional foods.

The application discloses a kind of nanobody specifically targeting human and murine NKG2D protein and its preparation method and application.The nanobody or antigen-binding fragment thereof of the application has three complementarity determining regions CDR1, CDR2 and CDR3;Wherein the amino acid sequences of CDR1, CDR2, CDR3 are as shown in SEQ ID NO.2, SEQ ID NO.3, SEQ ID NO.4 respectively.The nanobody can simultaneously bind hNKG2D and mNKG2D with high affinity, and the bispecific nanobody E5 / 2-B12 based on the nanobody can specifically bind CEACAM5 positive tumor cells and NKG2D overexpression cells, and effectively activate NK cells, which can significantly inhibit tumor growth and prolong survival in various tumor models, and has good application prospect in tumor immunotherapy.

The application discloses application of a pyrimidinotriazine diketone derivative in preparation of a medicine for inhibiting activity of human protease caspase-1, and belongs to the technical field of medicines. In view of defects of existing caspase-1 inhibitors, the compound has the characteristics of high affinity binding to caspase-1 (K D = 8.11 μM; 8.78 μM) and strong inhibition on the activity (IC 50 = 11.90 nM-14.47 nM). The compound is used for preparation of a medicine for inhibiting the activity of caspase-1 and a medicine for treating inflammation-related diseases such as sepsis-related lung injury, acute respiratory distress syndrome or acute pancreatitis.

The invention relates to the technical field of organelle separation, and provides a method for rapid purification of peroxisome and oxidation regulation analysis of ultra-long chain fatty acid. The method comprises the following steps: introducing a nucleic acid sequence for coding a fusion protein into a target cell to obtain a cell material, the fusion protein comprising a truncated sequence derived from a peroxisome membrane protein and a tag sequence for affinity purification; taking the cell material as a sample, and separating the peroxisome with the fusion protein from the cell by utilizing an affinity ligand on the basis of a high affinity binding principle. Therefore, according to the method disclosed by the invention, the peroxisome can be rapidly and efficiently enriched, and the whole purification process can be completed within 30 minutes, so that the experimental period is greatly shortened; core protein components of target organelles can be efficiently reserved, and the metabolic activity of peroxisome can be maintained through a complete membrane structure and an internal environment; meanwhile, the same purified sample can synchronously support proteome and metabolome analysis, and direct association of'protein-metabolism 'data is realized.

The invention discloses a method for preparing a VA-ECMO lung injury treatment medicine by using ginkgolide A to regulate YARS1, and relates to the technical field of biological medicine, the method comprises the following steps: by using ginkgolide A as a YARS1 protein regulator, preparing the medicine for treating the VA-ECMO lung injury through virtual screening, binding affinity confirmation and cell efficacy confirmation; wherein the virtual screening is based on a protein structure model of YARS1, and bilobalide A with high affinity binding energy with YARS1 is screened out through molecular docking. It is proved that ginkgolide A can effectively improve the lung ventilation function by regulating YARS1, repair the alveolar epithelial barrier structure and inhibit the inflammatory oxidative stress reaction, and the lung injury treatment effect and clinical transformation safety under the support of VA-ECMO are improved.

The invention discloses a nanometer antibody of mycobacterium tuberculosis early secretory protein ESAT-6 and application thereof, relates to the technical field of antibody recombination and genetic engineering antibodies, and is characterized by providing two nanometer antibodies AEN1 and AEN5 which are derived from a total synthesis alpaca nanometer antibody yeast display library and are combined with ESAT-6 in high affinity, DNA sequences for coding the AEN1 and the AEN5, a carrier containing the DNA, a carrier containing the carrier containing the DNA, and a carrier containing the carrier containing the carrier containing the DNA. The invention relates to a vector, a host cell containing the vector, and a method for preparing AEN1 and AEN5 by utilizing genetic engineering. And the method for quantitatively detecting the ESAT-6 by using the double-antibody sandwich ELISA is established. Detection on clinical specimens of tuberculosis shows that the sensitivity of the diagnosis method is 94.9%, and the specificity is 100%. The antibody is used for preparing gold-labeled rapid test paper, and the ESAT-6 can be rapidly detected from serum of a mycobacterium tuberculosis infected patient.

The present invention relates to a bispecific anti-tumor antigen / anti-HSG antibody having screened light and heavy chain variable domains, which is capable of improving the pre-targeting of tumors for the specific delivery of therapeutic or diagnostic agents. The antibodies have a significant affinity for tumor antigens and stay at desired sites for a sufficient time. Antibodies that do not bind to the antigen can be rapidly cleared from the body, minimizing exposure of normal tissue. A humanized anti-HSG antibody is bound to each of a group containing histamine-succinyl-glycine (HSG) and a tumor antigen with high affinity. The bispecific antibodies can be further Fc silenced, resulting in additional properties, such as reduced binding to Fc [gamma] R and FcRn, thereby modulating effector function and regulating half-life. These antibodies are useful in the diagnosis and treatment of subjects suffering from malignancies.

The invention discloses a nano antibody specifically combined with CD176 protein and application thereof, the nano antibody sequentially comprises a CDR1 region, a CDR2 region and a CDR3 region, the amino acid sequence of the CDR1 region is shown as SEQ ID No.6, the amino acid sequence of the CDR2 region is shown as SEQ ID No.7, and the amino acid sequence of the CDR3 region is shown as SEQ ID No.8. The invention further discloses a preparation method of the nano antibody specifically combined with the CD176 protein and application of the nano antibody specifically combined with the CD176 protein. The invention discovers that the nano antibody with the three complementary determining regions can be combined with CD176 protein (EC50 is 8.617 nM) with high affinity, has the characteristics of small molecular weight, small immunogenicity, better solubility and stability and the like, can effectively detect the expression of CD176 or inhibit the activity of CD176, and has potential value in the aspects of tumor detection and treatment.

The invention belongs to the field of biological medicines, and particularly relates to a specific binding protein of IL-4R as well as a preparation method and application of the specific binding protein. The invention provides a specific binding protein of IL-4R, which has specific CDRs, can be bound with human IL4R alpha in a high affinity manner, and can block the interaction of IL4R alpha-IL4 / IL13-IL13R alpha1 and the corresponding intracellular signal transduction and biological effect.

Provided is relating to the field of disease treatment, and in particular, to an anti-CDH3 antibody or an antigen-binding fragment thereof, a nucleic acid molecule encoding the same and a method for preparing the same. The anti-CDH3 antibody or the antigen-binding fragment thereof has high affinity binding and endocytosis activities for CDH3, while exhibiting high specificity. Provided is furtherly relating to the use of the antibody or the antigen-binding fragment thereof in the treatment and diagnosis of diseases.

The application relates to the technical field of biopharmaceuticals, and discloses a PD-1 and CTLA-4 double-target inhibiting polypeptide or a pharmaceutically acceptable salt thereof and an application thereof, wherein the polypeptide has a structure as shown in formula (I): X1SPILYQMCDYKRX2 (I). The polypeptide or the pharmaceutically acceptable salt thereof can simultaneously produce high-affinity binding to PD-1 and CTLA-4, has excellent biological blocking activity, can significantly improve the proportion of effector T cell subgroups in tumor tissues, and effectively enhances the anti-tumor immune response of the body. Therefore, the polypeptide or the pharmaceutically acceptable salt thereof can be used for related detection of PD-1 and CTLA-4, and can be used as a new anti-tumor candidate drug, thereby providing a brand-new treatment scheme for cancer patients.

Antibodies that target VZV glycoprotein E (gE) bind to recombinant gE with high affinity, bind to gE on the surface of VZV infected cells, interact with immune system effectors (e.g., Fc receptors), mediate antibody-dependent cellular cytotoxicity (ADCC) as well as Antibody Dependent Cellular Phagocytosis (ADCP), and prevent VZV infection of cells.

The present invention relates to polypeptides which are covalently bound to aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of PD-L1. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and / or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by PD-L1.

The present invention relates to immunoglobulins that bind IgE and FcγRIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.

The present invention relates to polypeptides which are covalently bound to non-aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of the Eph receptor tyrosine kinase A2 (EphA2). The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and / or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder characterised by overexpression of EphA2 in diseased tissue (such as a tumour).

On one hand, the invention discloses an anti-FOLR1 single-domain antibody VHH-F01, the amino acid sequence of the VHH-F01 is as shown in SEQ ID NO: 2, and the gene sequence of the VHH-F01 is as shown in SEQ ID NO: 1. The invention also discloses an umbilical cord mesenchymal stem cell preparation, which is characterized in that the preparation introduces the single-domain antibody VHH-F01 targeting the human FOLR1 and the gene of the human Bcl-2 anti-apoptotic protein into umbilical cord mesenchymal stem cells together through a lentiviral vector to obtain a stable and high-expression cell population; vHH-F01 expressed on the membrane surface of the preparation can specifically recognize ovarian cancer cells highly expressed by FOLR1 and can be combined with the ovarian cancer cells highly expressed by FOLR1 with high affinity, and meanwhile, the survival ability of stem cells in a tumor microenvironment can be remarkably enhanced by intracellular highly expressed Bcl-2 protein. In-vitro and animal experiments show that the preparation has excellent targeting homing efficiency and remarkable tumor inhibition effect on ovarian cancer tissues, can effectively prolong the lifetime of model animals, and provides a novel efficient targeting treatment tool for cell therapy of ovarian cancer.

The invention provides an anti-Claudin18.2 humanized single-domain antibody and a preparation method of the anti-Claudin18.2 humanized single-domain antibody. Specifically, the invention provides a Claudin18.2-targeted single-domain antibody, a humanized antibody thereof, a derivative protein, a gene sequence for encoding the Claudin18.2-targeted single-domain antibody, and an expression vector and an expression system for producing the Claudin18.2-targeted single-domain antibody. The single-domain antibody has high specificity, is combined with Claudin18.2 with high affinity and is basically not combined with Claudin18.1, and the single-domain antibody provides a research and development basis for development of antibody drugs, antibody coupling drugs and multi-specific antibody drugs.

The invention discloses a CDR region of a nano antibody targeting an Ebola virus. The invention also discloses a nano antibody BC2, which comprises the CDR region of the nano antibody targeting the Ebola virus. The invention also discloses a fusion protein antibody. The invention also discloses a polynucleotide, an expression vector, a host cell and an antibody conjugate. The invention also discloses application of the CDR region of the nano antibody, the nano antibody BC2, the fusion protein antibody and the antibody conjugate. The invention also discloses a pharmaceutical composition. The CDR region of the nano antibody targeting the Ebola virus, the nano antibody BC2 and the fusion protein antibody can be simultaneously combined with GP proteins of three subtypes of Ebola viruses with high affinity, can neutralize the Ebola virus in a broad spectrum, and can be used for preparing a reagent and a kit for detecting the Ebola virus; the compound can be used for preparing vaccines or medicines for treating and / or preventing Ebola virus infection.

The invention provides a Trop2-combined nano antibody as well as a product and application thereof, and relates to the technical field of antibodies. The invention discloses a nano antibody specifically binding to Trop2 protein, and a VHH sequence and a corresponding CDR sequence of the nano antibody. The nano antibody has the capability of high-affinity binding to target protein, and the nano antibody subjected to humanized modification still keeps the high-affinity binding characteristic.

The invention provides a nucleic acid molecule capable of being combined with oxytetracycline in a high-affinity mode. The nucleic acid molecule can detect the oxytetracycline with high sensitivity after being labeled with a fluorescent dye. Nucleic acid molecules (SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 or SEQ ID NO: 5) capable of specifically recognizing oxytetracycline are used as affinity ligands, and sensitive detection of oxytetracycline is realized by using nucleic acid molecules marked with fluorescent dye. According to the detection method disclosed by the invention, the detection limit of oxytetracycline reaches nM level, and the sensitivity is high.

Monoclonal antibodies that bind glypican-2 (GPC2) with high affinity are described. Immunotoxins and chimeric antigen receptors (CARs) that include the disclosed antibodies or antigen-binding fragments thereof are further described. In some instances, the antibody or antigen-binding fragment is humanized. The disclosed GPC2-specific antibodies and conjugates can be used, for example, for the diagnosis or treatment of GPC2-positive cancers, including neuroblastoma, medulloblastoma and retinoblastoma.

The invention relates to the technical field of biological medicines, in particular to a CD3 specific binding protein as well as a preparation method and application thereof. The CD3 specific binding protein provided by the embodiment of the invention has specific CDRs, can be combined with human and monkey CD3 epsilone delta dimer protein with high affinity, and has Jurkat cell binding activity.

Disclosed herein is a method for obtaining antibody-producing cells that express antibody molecules exhibiting high binding affinity to an antigen, comprising: contacting a population of antibody-producing cells, including cells expressing antibody molecules against an antigen on their cell surface, with a first labeled form of the antigen to enable the antigen to bind to antibody molecules on the cell surface; subsequently contacting the cells with (i) an unlabeled form of the antigen, (ii) a second labeled form of the antigen, or (iii) both the unlabeled and second labeled forms of the antigen; and collecting cells that remain bound to the first labeled form of the antigen, thereby obtaining cells that express antibody molecules with high affinity to the antigen. This method makes it possible to obtain cells expressing high-affinity antibody molecules from a pool of antibody-producing cells expressing antibody molecules with different affinities.

The invention discloses three potential bovine colostrum protein peptides with immunoregulatory activity and a preparation method of the three potential bovine colostrum protein peptides. The amino acid sequences of the active peptide are KTTMPLW, RDMPIQAF and SRYPSYGL respectively, and the active peptide has high affinity binding with a TLR2 / TLR4-MD-2 receptor through molecular docking verification. The method comprises the following steps: screening optimal protease on the basis of a virtual enzyme digestion technology and a quantitative structure-activity relationship (QSAR) model, carrying out enzymolysis on bovine colostrum protein by adopting alkaline protease, and carrying out ultrafiltration to obtain lt; and finally, carrying out LC-MS / MS (liquid chromatography-mass spectrometry / mass spectrometry) identification and bioinformatics screening to obtain a target peptide fragment. The invention provides a new technical scheme for high-value utilization of bovine coloctrum and development of functional immunoregulation food.

The present invention relates to polypeptides which are covalently bound to non-aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of PD-L1. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and / or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by PD-L1.

The invention relates to the technical field of biological pharmacy, and provides a double-target inhibition polypeptide or pharmaceutically acceptable salt and application thereof, the polypeptide comprises an amino acid sequence: TASPILYQMCCDYKR, and an amino acid fragment: X1WGIX2HSHFTHTX3WKX4 (I) with a structure as shown in a formula (I) is connected to the C tail end of the sequence. The polypeptide or the pharmaceutically acceptable salt thereof can generate high-affinity binding with PD-1 and CTLA-4 at the same time, has excellent biological blocking activity, can significantly improve the proportion of effector T cell subsets in tumor tissues, and effectively enhances the anti-tumor immune response of a body. Therefore, the polypeptide or the pharmaceutically acceptable salt thereof can be used for related detection of PD-1 and CTLA-4, can also be used as a novel anti-tumor candidate drug, and provides a brand new treatment scheme for cancer patients.